

S Senan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10861815/publications.pdf>

Version: 2024-02-01

44
papers

5,869
citations

279487

23
h-index

288905

40
g-index

45
all docs

45
docs citations

45
times ranked

6483
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv1-iv21. | 0.6 | 1,456 |
| 2 | Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016, 27, v1-v27. | 0.6 | 1,351 |
| 3 | Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 685-692. | 0.4 | 510 |
| 4 | Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013, 24, vi89-vi98. | 0.6 | 440 |
| 5 | 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, 1462-1474. | 0.6 | 410 |
| 6 | Stage II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. <i>Annals of Oncology</i> , 2013, 24, 1543-1548. | 0.6 | 261 |
| 7 | Multiple CT scans for incorporating lung tumor mobility in radiotherapy planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 932-937. | 0.4 | 191 |
| 8 | Early-stage lung cancer in elderly patients: A population-based study of changes in treatment patterns and survival in the Netherlands. <i>Annals of Oncology</i> , 2012, 23, 2743-2747. | 0.6 | 147 |
| 9 | Evaluation of a target contouring protocol for 3D conformal radiotherapy in non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 1999, 53, 247-255. | 0.3 | 139 |
| 10 | Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. <i>Annals of Oncology</i> , 2020, 31, 798-806. | 0.6 | 131 |
| 11 | Analysis and reduction of 3D systematic and random setup errors during the simulation and treatment of lung cancer patients with CT-based external beam radiotherapy dose planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 857-868. | 0.4 | 114 |
| 12 | Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study. <i>British Journal of Cancer</i> , 2006, 94, 625-630. | 2.9 | 88 |
| 13 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, ISMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2020, 31, 191-201. | 0.6 | 70 |
| 14 | Fractionated high-dose-rate brachytherapy in primary carcinoma of the nasopharynx. <i>Journal of Clinical Oncology</i> , 1998, 16, 2213-2220. | 0.8 | 62 |
| 15 | An analysis of anatomic landmark mobility and setup deviations in radiotherapy for lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 43, 827-832. | 0.4 | 56 |
| 16 | Dosimetric consequences of tumor mobility in radiotherapy of stage I non-small cell lung cancer: an analysis of data generated using CT scans. <i>Radiotherapy and Oncology</i> , 2001, 61, 93-99. | 0.3 | 52 |
| 17 | Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review. <i>ESMO Open</i> , 2021, 6, 100244. | 2.0 | 40 |
| 18 | Defining target volumes for non-small cell lung carcinoma. <i>Seminars in Radiation Oncology</i> , 2004, 14, 308-314. | 1.0 | 39 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity. <i>Annals of Oncology</i> , 2011, 22, 132-138. | 0.6 | 39 |
| 20 | Normal Tissue Complication Probability Modeling of Pulmonary Toxicity After Stereotactic and Hypofractionated Radiation Therapy for Central Lung Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 738-747. | 0.4 | 36 |
| 21 | Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. <i>Clinical Cancer Research</i> , 1997, 3, 31-8. | 3.2 | 35 |
| 22 | An evaluation of two techniques for beam intensity modulation in patients irradiated for stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2001, 32, 145-153. | 0.9 | 25 |
| 23 | Stereotactic radiotherapy for stage I lung cancer: Current results and new developments. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2010, 14, 115-118. | 0.6 | 25 |
| 24 | Stereotactic ablative radiotherapy (SABR) for early-stage central lung tumors: New insights and approaches. <i>Lung Cancer</i> , 2018, 123, 142-148. | 0.9 | 18 |
| 25 | BRACHYTHERAPY FOR RECURRENT HEAD AND NECK CANCER. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 531-542. | 0.9 | 14 |
| 26 | Trimodality therapy for stage IIIA non-small cell lung cancer: Benchmarking multi-disciplinary team decision-making and function. <i>Lung Cancer</i> , 2014, 85, 218-223. | 0.9 | 13 |
| 27 | Reply: Patterns of nodal recurrence after omission of elective nodal irradiation for limited-stage small-cell lung cancer. <i>British Journal of Cancer</i> , 2007, 97, 276-276. | 2.9 | 12 |
| 28 | The role of radiotherapy in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2005, 16, ii223-ii228. | 0.6 | 11 |
| 29 | Radiographic Changes After Lung Stereotactic Ablative Radiotherapy (SABR) – Can We Distinguish Fibrosis From Recurrence? A Systematic Review of the Literature. <i>Practical Radiation Oncology</i> , 2013, 3, S11-S12. | 1.1 | 11 |
| 30 | Patterns of care and outcomes for stage IIIB non-small cell lung cancer in the TNM-7 era: Results from the Netherlands Cancer Registry. <i>Lung Cancer</i> , 2017, 110, 14-18. | 0.9 | 11 |
| 31 | Esophagus toxicity after stereotactic and hypofractionated radiotherapy for central lung tumors: Normal tissue complication probability modeling. <i>Radiotherapy and Oncology</i> , 2018, 127, 233-238. | 0.3 | 10 |
| 32 | Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial. <i>ESMO Open</i> , 2022, 7, 100410. | 2.0 | 10 |
| 33 | Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapy. <i>Annals of Oncology</i> , 2015, 26, 2196. | 0.6 | 9 |
| 34 | Treatment patterns for adrenal metastases using surgery and SABR during a 10-year period. <i>Radiotherapy and Oncology</i> , 2022, 170, 165-168. | 0.3 | 9 |
| 35 | Population-based Results of Chemoradiotherapy for Limited Stage Small Cell Lung Cancer in The Netherlands. <i>Clinical Oncology</i> , 2018, 30, 17-22. | 0.6 | 6 |
| 36 | The diagnosis and treatment of nasal lymphoma, an important cause of upper respiratory tract destruction. <i>Clinical Otolaryngology</i> , 1992, 17, 563-566. | 0.6 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | The use of CT-simulation and digitally reconstructed radiographs (DRR's) in setup verification allows for smaller planning target volumes in lung cancer. <i>Lung Cancer</i> , 2000, 29, 162. | 0.9 | 3 |
| 38 | Stereotactic body radiotherapy for central lung tumours. <i>British Journal of Radiology</i> , 2015, 88, 20150410. | 1.0 | 3 |
| 39 | Is radical chemo-radiotherapy appropriate in patients with stage IV non-small-cell lung cancer due to cervical lymph node metastases?. <i>Annals of Oncology</i> , 2016, 27, 1973. | 0.6 | 1 |
| 40 | Lack of consensus on post-operative radiotherapy (PORT) fields used in non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2007, 25, 7658-7658. | 0.8 | 0 |
| 41 | Outcomes of stereotactic body radiotherapy (SBRT) in 175 patients with stage I NSCLC aged 75 years and older. <i>Journal of Clinical Oncology</i> , 2009, 27, 9545-9545. | 0.8 | 0 |
| 42 | TH-A-WAB-11: A Novel Method to Determine Alpha/beta for Irradiated Normal Lung Tissue Using Computed Tomography Scans. <i>Medical Physics</i> , 2013, 40, 522-522. | 1.6 | 0 |
| 43 | WE-AB-202-02: Incorporating Regional Ventilation Function in Predicting Radiation Fibrosis After Concurrent Chemoradiotherapy for Lung Cancer. <i>Medical Physics</i> , 2016, 43, 3794-3794. | 1.6 | 0 |
| 44 | ADRIATIC: Eine Phase-III-Studie mit Durvalumab ± Tremelimumab nach gleichzeitiger Radiochemotherapie für Patienten mit SCLC im Stadium Limited Disease. , 2020, 74, . | | 0 |